Semaglutide Before & After: What the Trial Numbers Show

Search "semaglutide before and after" and you get photo galleries. This compound does not need them. Unlike almost everything else covered on this site, semaglutide has a real, measured before and after — thousands of people weighed on calibrated scales in randomized trials — and the numbers are better than the photos in every way that matters.

Here is the measured version: adults without diabetes on weekly semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, against 2.4% with placebo. About 86% lost at least 5%, 69% lost at least 10%, and half lost 15% or more¹. In a separate head-to-head trial, 38.5% reached a 20% loss². The loss happens mostly in the first year, flattens into a plateau, and — the part no photo gallery shows — reverses when the drug stops: a year after withdrawal, trial participants had regained two-thirds of what they lost⁶.

That distribution, that timeline, and that regain curve are what an honest before-and-after looks like. This page walks through each, and through what transformation photos systematically leave out.

How Much Weight Do People Actually Lose?

The single most quoted number is STEP 1's 14.9% average at 68 weeks — a mean 15.3 kg, about 34 lb¹, in trial populations that started around 104 to 106 kg (roughly 230 lb)²⁴. Wegovy, the brand of semaglutide approved for weight management, is this trial's drug at this trial's 2.4 mg dose.

An average, though, is the least useful way to read a weight-loss trial, because responses spread widely. The same trial reports the spread directly¹:

• •86.4% of semaglutide participants lost at least 5% (versus 31.5% on placebo)
• •69.1% lost at least 10% (versus 12.0%)
• •50.5% lost at least 15% (versus 4.9%)

STEP 8, which ran semaglutide against daily liraglutide, adds the top band: 38.5% of semaglutide participants reached a 20% loss, versus 6.0% on liraglutide². Read from the other end, the same data say that 13.6% of STEP 1's semaglutide group did not reach even the 5% mark¹. Both tails are real. A gallery shows you one of them.

So the honest expectation is a range: the middle of the distribution lands between 10% and 15% at 68 weeks, a large minority does substantially better, and a measurable minority gets little. Why a given person lands where they land is not something the trials can predict in advance — which is exactly why a stranger's photos tell you nothing about your own outcome. The mechanism behind the loss — appetite suppression through GLP-1 receptor agonism — is covered in how semaglutide works.

When Does the Loss Actually Happen?

Semaglutide is titrated: the STEP trials escalated the dose over 16 weeks before holding at 2.4 mg⁶, a schedule explained in semaglutide dosage. The loss starts during escalation and is front-loaded into the first year. The trial record gives clean milestone numbers:

Two things stand out. First, about 70% of the eventual loss is already in place by week 20³. Second, the two-year figure (−15.2%)⁴ is essentially the 68-week figure (−14.9%)¹ — the curve flattens into a plateau rather than compounding. In the SELECT trial, which followed patients for four years, weight loss continued over 65 weeks and was then sustained, not extended⁵.

The plateau is not the drug failing. It is the new equilibrium between a suppressed appetite and a lighter body, and it is where maintenance begins. Anyone selling a timeline in which month 18 looks dramatically better than month 12 is not describing this drug.

Ozempic vs. Wegovy: Same Molecule, Different Dose

Both brand names belong to the same molecule. Ozempic is semaglutide approved for type 2 diabetes at lower maintenance doses; Wegovy is semaglutide at 2.4 mg approved for weight management. STEP 2 tested the weight question directly in people with type 2 diabetes and found a mean loss of 9.6% with 2.4 mg versus 3.4% with placebo at 68 weeks⁸ — meaningfully less than the 14.9% seen in people without diabetes¹. So "Ozempic before and after" photos mix two things that should not be averaged: lower doses, and a population that predictably loses less.

Starting point matters in the other direction too. STEP 3 paired semaglutide with intensive behavioral therapy — 30 counseling visits and an initial low-calorie diet — and the semaglutide group reached −16.0%; the striking change was the placebo arm, which reached −5.7%, more than double placebo's loss in STEP 1⁹. Intensive lifestyle work moves the baseline everyone is measured against, which is worth remembering when a clinic's gallery bundles the drug with a coached program.

For how these numbers compare with the other major GLP-1 — where tirzepatide's top dose produced a 20.9% mean loss over 72 weeks, with 57% of that group reaching a 20% loss¹⁰ — see tirzepatide vs semaglutide.

Is the Loss Fat or Muscle?

A scale cannot tell you what the weight was. DEXA scans can, and a randomized substudy did them: with semaglutide 1.0 mg over 52 weeks in type 2 diabetes, total fat mass fell by 3.4 kg — and total lean mass also fell, by 2.3 kg. The proportion of lean mass rose slightly (by 1.2 percentage points), because fat was lost faster than lean, but roughly 40% of the kilograms lost were not fat⁷.

That ratio is typical of substantial weight loss by most means, not a unique defect of semaglutide — but it is invisible in a photograph and absent from every gallery caption. It is also the strongest practical argument for resistance training and adequate protein during treatment. We cover the evidence in detail in semaglutide, tirzepatide, and muscle loss, and the facial version of the same arithmetic — rapid fat loss reads as aging in the face — in Ozempic face: what the evidence says.

What Happens After the "After" Photo?

Every before-and-after ends at the flattering frame. The trials kept measuring.

STEP 4 put everyone on semaglutide for 20 weeks (mean loss: 10.6%), then randomized: those who continued lost another 7.9% over the following 48 weeks, while those switched to placebo regained 6.9%³. The curves fork immediately at withdrawal.

The STEP 1 extension followed 327 participants for a year after both drug and lifestyle support stopped. On treatment they had lost 17.3%; a year off it, they had regained 11.6 percentage points of that — two-thirds of the loss — leaving a net 5.6% below where they started, with cardiometabolic improvements reverting toward baseline as well⁶.

This is the least marketed and most important fact on this page. Semaglutide treats an ongoing condition the way blood-pressure medication does; it is not a course you complete. Any before-and-after that does not say whether the person is still taking it is missing its most predictive variable. Stopping, restarting, and dose questions belong with a prescriber — the safety side is covered in is semaglutide safe.

What the Photo Galleries Systematically Hide

None of this requires the photos to be fake — the trial data say most people on 2.4 mg genuinely lose visible amounts of weight. The problem is what a gallery, honestly assembled, still cannot show.

• •Selection. The 38.5% who reach a 20% loss² photograph well. The 13.6% who did not reach 5%¹ do not post.
• •The endpoint is chosen. Photos are taken at the plateau, not a year after stopping, when two-thirds of the change has typically reversed⁶.
• •Posture, lighting, and clothing move apparent body composition more than a month of treatment does — the same confounds we document for sermorelin before and after and BPC-157 before and after apply to a drug that works, too.
• •Lean loss is invisible. A DEXA scan sees the 2.3 kg of lean mass that went with the fat⁷; a photograph reads it as "slimmer."
• •The program travels with the drug. Trial participants got lifestyle intervention alongside semaglutide¹, and STEP 3 shows intensive coaching alone produced a 5.7% loss⁹.

A gallery also cannot show the other visible change some users report during rapid loss — temporary hair shedding, which has its own evidence page in semaglutide and hair loss.

What the Timeline Costs

Because the drug works on a schedule measured in months and the dose escalates, pricing that looks flat rarely is. Two verified examples from our provider reviews: Carocare Wellness starts compounded semaglutide at $170 for month 1, but on its dose-escalating schedule the price climbs steeply — reaching $330 a month by month 5. And NuuVim advertises "$79/month", which is a first-three-months, new-patient rate billed as one $237 lump sum; NuuVim's own pricing page lists the "Current User" renewal rate at $133/month ($399 every three months), a jump the homepage banner never mentions.

The pattern — an entry price standing in for the price of the months where the results actually happen — is the single most common trap in this category. Per-provider figures live on best semaglutide providers and in the price transparency index; the cost landscape as a whole is in semaglutide cost. If you are prescribed compounded semaglutide in a vial rather than a pen, the semaglutide dosage calculator converts a milligram dose to syringe units for your vial's concentration — and the legal status of compounded product is its own moving question, tracked in is compounded semaglutide legal. Several sellers, NuuVim included, also offer tablet forms — a different evidence question entirely, covered in oral peptides for weight loss.

Bottom Line

Semaglutide has the best-documented before and after of any compound this site covers, and it does not need a photo. The before: trial populations averaging roughly 105 kg²⁴. The after: a mean 14.9% loss at 68 weeks, half of participants down 15% or more, the curve flat from about the one-year mark onward¹⁴ — less in type 2 diabetes⁸, with a meaningful share of the lost kilograms coming from lean mass⁷. And the after-the-after: two-thirds of the loss regained within a year of stopping⁶.

Judge any transformation photo against those four numbers. If it shows more, ask what else changed; if it promises the result persists without the drug, the extension data already answered that. For the wider drug-class picture, see peptide injections for weight loss, peptides for fat loss, and is Ozempic a peptide.

This page is educational and not medical advice. Decisions about starting, dosing, or stopping semaglutide belong with a licensed clinician who knows your history.